Associated Papers
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.
Abrehdari-Tafreshi Z et al.
Biochemical Genetics, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.
Detiger SE et al.
Clinical Immunology (orlando, Fla.), 2024
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study.
Jiang H et al.
Translational Lung Cancer Research, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z et al.
Journal of Clinical Laboratory Analysis, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Ophthalmic manifestations in Costello syndrome caused by Ras pathway dysregulation during development.
Shankar SP et al.
Ophthalmic Genetics, 2022
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U et al.
European Journal of Cancer (oxford, England : 1990), 2021
KRAS mutations in implant-associated peripheral giant cell granuloma.
Martins-Chaves RR et al.
Oral Diseases, 2020
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
Gong J et al.
Oncotarget, 2017
BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.
Summers MG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
Jones RP et al.
British Journal of Cancer, 2017
K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T et al.
Medical Oncology (northwood, London, England), 2016
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Clinical and Experimental Medicine, 2016
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
Haley L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
Piton N et al.
Gastroenterology Research and Practice, 2015
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N et al.
Journal of Clinical Pathology, 2014
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A et al.
Cancer Medicine, 2014
Melting curve analysis for mutations of EGFR and KRAS.
Furugaki K et al.
Anticancer Research, 2014
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G et al.
Clinical Lung Cancer, 2014
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM et al.
Clinical Colorectal Cancer, 2013
[KRAS gene mutation in colorectal cancer].
Roa I et al.
Revista Medica De Chile, 2013
Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP et al.
Annals of Surgical Oncology, 2013
The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F et al.
Genetic Testing and Molecular Biomarkers, 2013
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F et al.
Cancer Research, 2013
HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T et al.
Journal of Human Genetics, 2011
Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.
Gremer L et al.
Biological Chemistry, 2008
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
Oliveira C et al.
Oncogene, 2007
Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI et al.
Gynecologic Oncology, 2006